

This invention relates to an improved method of cancer therapy that involves treating a patient with both an anthracycline antibiotic (e.g., doxorubicin) and a cyclic GMP-specific phosphodiesterase (PDE) inhibitor. The specific PDE inhibitors useful for this invention are compounds that inhibit both PDE5 and the new cGMP-specific PDE described below. The novel cGMP-PDE is fully described by Liu, et al., U.S. Patent No. 6,200,771 in the copending U.S. Patent Application Serial No. \_\_\_\_\_ (Case No. P-143), A Novel Cyclic GMP Specific Phosphodiesterase And Methods For Using Same In Pharmaceutical Screening For Identifying Compounds For Inhibition Of Neoplastic Lesions. (For general PDE background, see, Beavo, J.A. (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiological Reviews 75:725-747; web site <http://weber.u.washington.edu/~pde/pde.html> (Nov.1998)).

Please amend the paragraph on page 7, line 22 to page 8, line 2 by replacing it with the following amended paragraph:

The novel cGMP-specific phosphodiesterase can be isolated from human carcinoma cell lines (e.g. SW-480, a human colon cancer cell line that originated from a moderately differentiated epithelial adenocarcinoma, available from the American Tissue Type Collection in Rockville, Maryland, U.S.A.). The complete isolation of this new cGMP-PDE is described in ~~the copending application, Liu, et al, U.S. Patent No. 6,200,771 in the copending U.S. Patent Application Serial No. \_\_\_\_\_ (Case No. P-143), A Novel Cyclic GMP Specific Phosphodiesterase And Methods For Using Same In Pharmaceutical Screening For Identifying Compounds For Inhibition Of Neoplastic Lesions,~~ which is incorporated herein by reference.

#### Remarks

The disclosure was objected to for the informality of the missing Serial No. on page 7. That informality, as well as a corresponding one on page 3, has been corrected by inserting the resulting patent No. at the appropriate places. Applicants respectfully submit that the informalities have been corrected.